President Donald Trump’s drug-pricing platform TrumpRx is expanding to offer 600 generic medications — and partner with billionaire “Shark Tank” investor Mark Cuban.
The growth of the federally run website launched earlier this year is meant to ensure consumers get “the lowest possible cost on their prescription,” Trump said alongside Cuban at a Monday press conference at the White House.
TrumpRx.gov has been revamped to enable visitors to find generic versions of brand-name drugs with just one click. They can also access maps showing different prices for drugs in their neighborhoods, as well as delivery services.
“For decades, Americans paid the highest drug prices anywhere in the world, by far,” Trump said. “We now pay the lowest price paid for anybody in any country.”
TrumpRx which doesn’t sell medicine, but points visitors to websites that do. Those now include the Mark Cuban Cost Plus Drug Company, which ships mail-order medications directly to consumers.
“Republicans want cheaper drugs, independents want cheaper drugs, Democrats want cheaper drugs. And together, I think we’re going to do something special,” said Cuban, one of the country’s most outspoken critics of opaque pharmaceutical pricing systems.
He was also a vocal foe of Trump’s during the 2024 presidential contest, when he endorsed Democratic candidate Kamala Harris and told Fox Business: ” I think [Trump] was a lousy president before, I think he’ll be a worse president this time.”
Trump let bygones be bygones on Monday.
“He made a mistake. It was a big mistake,” he said with a smile. “He’s got a good company and he’s going to do a lot of business through this.”
As one example of how the revamped website works, the press conference brought up the TrumpRx.gov search result for diabetes drug Glucophage, which goes for around $20. The search yielded the generic version of the drug, metformin, for $8.42.
The administration has been touting its agreements with drugmakers to lower prices for government programs and offer medications directly to consumers as part of a broader healthcare affordability push.
TrumpRx advertises steep discounts on dozens of brand-name medications through “Most Favored Nation” pricing deals negotiated with pharmaceutical manufacturers.
The site initially listed dozens of branded drugs ranging from diabetes and weight-loss medications to fertility treatments, cancer drugs and respiratory inhalers.
A number of the currently available medications are advertised at discounts exceeding 80% off their original list prices.
Wegovy, a weight-loss medication, is listed as “starting at $149” compared with an original price of $1,349.02 — an 89% discount, according to the TrumpRx website.
Ozempic, a diabetes treatment that has become wildly popular for weight loss, too, is listed starting at $199 compared with a list price of $1,027.51.
The site advertises the fertility treatment Cetrotide at $22.50, down from $316.12, while diabetes drug Jentadueto is listed at $55 compared with a price of $525.08.
Other heavily discounted drugs include Mayzent for multiple sclerosis, listed as “starting at $42” instead of $623; Farxiga, listed at $35 instead of $377.82; and Amjevita, a Humira biosimilar, listed at $299 instead of $1,484.16.
The discounts are part of a White House-backed effort to pressure drugmakers into lowering prices for American consumers by tying domestic pricing more closely to rates charged overseas.
The platform has expanded as more pharmaceutical manufacturers signed agreements with the administration.
Boehringer Ingelheim added diabetes drugs Jentadueto and Jentadueto XR, as well as COPD inhaler Striverdi Respimat, to the platform.
Novartis agreed to provide access to Mayzent, leukemia treatment Rydapt and lung-cancer drug Tabrecta.
Amgen added migraine treatment Aimovig, cholesterol drug Repatha and Humira biosimilar Amjevita.
GSK added several inhalers including Incruse, Arnuity and Anoro Ellipta along with antiviral drug Relenza.
Cuban’s alignment with the administration’s drug platform highlighted the unusual political coalitions emerging around prescription-drug costs.
The businessman, who has long described himself as an independent and libertarian-leaning centrist, publicly supported the past several Dem presidential candidates — from Barack Obama and Hillary Clinton to Joe Biden and Harris.
In recent years, Cuban has pushed for lower generic-drug costs, greater price transparency and reforms aimed at middlemen in the pharmaceutical supply chain.
The billionaire entrepreneur has argued that middlemen known as pharmacy benefit managers prefer higher prices because they profit off of the system.
